Vaccine News and Research

Latest Vaccine News and Research

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Emergent BioSolutions completes sales, deliveries of BioThrax to allied international governments

Emergent BioSolutions completes sales, deliveries of BioThrax to allied international governments

Increased drug development cost drives pharma companies to seek better opportunities in emerging markets

Increased drug development cost drives pharma companies to seek better opportunities in emerging markets

Rapidly growing polio outbreak in Tajikistan raises serious concerns, states CMAJ

Rapidly growing polio outbreak in Tajikistan raises serious concerns, states CMAJ

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

Aphios awarded US patent for process to formulate polymeric microspheres, nanospheres

Aphios awarded US patent for process to formulate polymeric microspheres, nanospheres

BioSante closes $15 million registered direct offering

BioSante closes $15 million registered direct offering

Company took measures to protect employees from H1N1 flu: National poll

Company took measures to protect employees from H1N1 flu: National poll

US physicians concerned about health risk to patients from heat-damaged medicinal products

US physicians concerned about health risk to patients from heat-damaged medicinal products

European drugmakers lead in making medicines available to developing world, Index says

European drugmakers lead in making medicines available to developing world, Index says

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

Biovest targets mantle cell lymphoma as next indication for BiovaxID

Biovest targets mantle cell lymphoma as next indication for BiovaxID

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

Health leaders formally launch new strategy for polio eradication

Health leaders formally launch new strategy for polio eradication

Asthmatics to suffer more this winter warn experts

Asthmatics to suffer more this winter warn experts

Also in Global Health News: WHO scraps drug development group; Access to medication in Philippines; Yellow fever vaccine shortage; HIV-positive employee protection

Also in Global Health News: WHO scraps drug development group; Access to medication in Philippines; Yellow fever vaccine shortage; HIV-positive employee protection

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante announces $15 million registered direct offering

BioSante announces $15 million registered direct offering

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.